Carlo Dominici

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells.

BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells.

Journal: Cancer letters

Published: January 17, 2020

MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.

MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 08, 2019

Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.

Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.

Journal: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Published: January 11, 2019

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Journal: Journal of cancer research and clinical oncology

Published: December 17, 2018

Circ-ZNF609 regulates G1-S progression in rhabdomyosarcoma.

Circ-ZNF609 regulates G1-S progression in rhabdomyosarcoma.

Journal: Oncogene

Published: September 10, 2018

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.

Journal: Journal of cancer research and clinical oncology

Published: September 07, 2018

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.

Journal: Journal of hematology & oncology

Published: June 21, 2017

HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.

HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.

Journal: Cancer letters

Published: January 17, 2017

A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.

A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.

Journal: Oncology reports

Published: September 08, 2016

DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.

DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.

Journal: Oncotarget

Published: July 22, 2016

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 11, 2015

Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells.

Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells.

Journal: Oncotarget

Published: April 09, 2015

Showing 1-12 of 24

Last Updated: 09/26/2026